Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

NCT07334119 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-Expressing Solid Tumors

Interventions

DRUG: MT-304
DRUG: MT-304 + Nivolumab

Sponsor

Myeloid Therapeutics

Collaborators

[object Object]